Global Health Limited (NSE: Medanta, BSE: 543654) posted record financial results for Q1 FY26, reinforcing its leadership in the private multi-specialty healthcare sector in North and East India. Total income rose 19.1% year-on-year to ₹10,513 million, EBITDA grew 22.6% to ₹2,553 million, and Profit After Tax surged 49.6% to ₹1,590 million. Margins improved with PAT at 15.1% and EBITDA at 24.3%.
Key growth drivers included a 13.3% rise in occupied bed days, ARPOB improvement to ₹66,584, and double-digit growth in in-patient and out-patient counts. Mature hospitals delivered revenue of ₹7,006 million, while developing hospitals rose 35.9% to ₹3,219 million. International patient revenue jumped 33.8% to ₹636 million, and OPD pharmacy sales grew 21.6% to ₹404 million.
Medanta’s planned Northeast expansion is expected to significantly improve access to advanced tertiary care. Healthcare analysts note that patients currently rely heavily on Guwahati, Kolkata, or New Delhi for specialized treatment. A Medanta facility in the region could reduce medical travel costs, encourage local diagnostic services, and potentially stimulate related sectors like hospitality and transport. CEO Pankaj Sahni highlighted capacity additions in Ranchi and the upcoming 550-bed Noida hospital as part of a long-term growth strategy.
